PPH2018

Makoto Suematsu

President of the Japan Agency for Medical Research and Development (AMED)

Dr Makoto Suematsu is the President of the Japan Agency for Medical Research and Development (AMED). AMED was established in 2015 to progress medical innovation and overcome barriers between sectors by connecting talented individuals and groups with each other.

In the last two years, Dr Suematsu has led AMED to enter Memorandum of Cooperation agreements with several of their counterparts including the United States of America, the United Kingdom, Singapore, Spain and Lithuania.

Dr Suematsu also represents Japan on a number of overseas institutions and global consortiums including the International Rare Diseases Research Consortium, Global Research Collaboration for Infectious Disease Preparedness, Joint Programming Initiative on Antimicrobial Resistance and the International Human Epigenome Consortium.

Through a multitude of international partnerships, Dr Suematsu has enabled AMED to contribute significantly towards research and development, particularly in the fields of rare and undiagnosed diseases, infectious diseases and cancer research.

Prior to his role at AMED, Dr Suematsu was Dean of the Keio University School of Medicine in Japan from 2007.

Dr Suematsu’s research interests include gas biology and medicine, microcirculatory physiology, and exploring disease-specific biomarker molecules metabolomics.